Claims for Patent: 9,480,742

Summary for Patent: 9,480,742

Title:	Method of promoting bone growth by an anti-actriia antibody
Abstract:	In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density.
Inventor(s):	Knopf; John (Carlisle, MA), Seehra; Jasbir (Lexington, MA)
Assignee:	Acceleron Pharma Inc. (Cambridge, MA)
Application Number:	13/939,976
Patent Claims:	1. A method for promoting bone growth, increasing bone density, or increasing bone strength, the method comprising administering to a subject in need thereof an effective amount of an anti-ActRIIa antibody, wherein the anti-ActRIIa antibody antagonizes an activin-ActRIIa signaling pathway. 2. The method of claim 1, wherein the anti-ActRIIa antibody is a monoclonal antibody. 3. The method of claim 1, wherein the anti-ActRIIa antibody is a humanized or fully human antibody. 4. The method of claim 1, wherein the method is for promoting bone growth in a subject in need thereof. 5. The method of claim 1, wherein the method is for increasing bone density in a subject in need thereof. 6. The method of claim 1, wherein the method is for increasing bone strength in a subject in need thereof. 7. The method of claim 1, wherein the method further comprises administering a second bone-active agent. 8. The method of claim 7, wherein the bone-active agent is selected from: a bisphosphonate, an estrogen, a selective estrogen-receptor modulator, a parathyroid hormone, a calcitonin, a calcium supplement, and a vitamin D supplement. 9. A method for treating a bone-related disorder, the method comprising administering to a subject in need thereof an effective amount of an anti-ActRIIa antibody, wherein the bone-related disorder is associated with low bone density or decreased bone strength. 10. The method of claim 9, wherein the anti-ActRIIa antibody is a monoclonal antibody. 11. The method of claim 9, wherein the anti-ActRIIa antibody is a humanized or fully human antibody. 12. The method of claim 9, wherein the method further comprises administering a second bone-active agent. 13. The method of claim 12, wherein the bone-active agent is selected from: a bisphosphonate, an estrogen, a selective estrogen-receptor modulator, a parathyroid hormone, a calcitonin, a calcium supplement, and a vitamin D supplement. 14. The method of claim 9, wherein the bone-related disorder is primary osteoporosis. 15. The method of claim 9, wherein the bone-related disorder is post-menopausal osteoporosis. 16. The method of claim 9, wherein the bone-related disorder is secondary osteoporosis. 17. The method of claim 9, wherein the bone-related disorder is hypogonadal bone loss. 18. The method of claim 9, wherein the subject has a cancer that is associated with bone loss. 19. The method of claim 9, wherein the subject is the recipient of a cancer treatment regimen than is associated with bone loss. 20. The method of claim 9, wherein the bone-related disorder is bone metastases. 21. The method of claim 9, wherein the bone-related disorder is multiple myeloma. 22. The method of claim 9, wherein the bone-related disorder is Paget's disease. 23. The method of claim 9, wherein the subject has a cancer that is associated with bone metastases.

Details for Patent 9,480,742

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Takeda Pharmaceuticals U.s.a., Inc.	NATPARA	parathyroid hormone	For Injection	125511	January 23, 2015		2033-07-11